http://jnci.oxfordjournals.org/content/98/18/1285.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis
         
      </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/98/18/1285" />
      <meta content="/jnci/98/18/1285.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis"
            name="DC.Title" />
      <meta content="10.1093/jnci/djj357" name="DC.Identifier" />
      <meta content="2006-09-20" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Davide Mauri" name="DC.Contributor" />
      <meta content="Nicholas Pavlidis" name="DC.Contributor" />
      <meta content="Nikolaos P. Polyzos" name="DC.Contributor" />
      <meta content="John P. A. Ioannidis" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Davide Mauri" />
      <meta name="citation_author" content="Nicholas Pavlidis" />
      <meta name="citation_author" content="Nikolaos P. Polyzos" />
      <meta name="citation_author" content="John P. A. Ioannidis" />
      <meta content="Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis"
            name="citation_title" />
      <meta content="09/20/2006" name="citation_date" />
      <meta content="98" name="citation_volume" />
      <meta content="18" name="citation_issue" />
      <meta content="1285" name="citation_firstpage" />
      <meta content="1291" name="citation_lastpage" />
      <meta content="98/18/1285" name="citation_id" />
      <meta content="98/18/1285" name="citation_id_from_sass_path" />
      <meta content="jnci;98/18/1285" name="citation_mjid" />
      <meta content="10.1093/jnci/djj357" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/98/18/1285.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/18/1285.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/18/1285.full.pdf"
            name="citation_pdf_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/18/1285"
            name="citation_public_url" />
      <meta content="16985247" name="citation_pmid" />
      <meta name="citation_section" content="Article" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/98/18/1275.short" rel="prev" />
      <link href="/content/98/18/1292.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d29574244e1">var callbackToken='537695CDDE3E52F';</script><script type="text/javascript" id="session-d29574244e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:16:43.979-07:00';
            var gSessionId = 'oqhLzE0FA1K2HqnNo86R1g';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djj357");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20 September 2006");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F98%2F18%2F1285.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/98/18.toc">
                  <span xmlns="" class="volume-value">Volume 98</span>
                  <span xmlns="" class="issue-value"> Issue 18</span></a></li>
            <li>Pp. <span class="slug-pages">
                  1285-1291.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/98/18/1285.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Davide+Mauri&amp;sortspec=date&amp;submit=Submit">Davide Mauri</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Nicholas+Pavlidis&amp;sortspec=date&amp;submit=Submit">Nicholas Pavlidis</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Nikolaos+P.+Polyzos&amp;sortspec=date&amp;submit=Submit">Nikolaos P. Polyzos</a></span> and 
                     </li>
                     <li class="last" id="contrib-4"><span class="name"><a class="name-search"
                              href="/search?author1=John+P.+A.+Ioannidis&amp;sortspec=date&amp;submit=Submit">John P. A. Ioannidis</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><em>Affiliations of authors:</em> Department of Medical Oncology (DM, NP) and Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology
                           (NPP, JPAI), University of Ioannina School of Medicine, Ioannina, Greece; Biomedical Research Institute, Foundation for Research
                           and Technology-Hellas, Ioannina, Greece (JPAI); Institute for Clinical Research and Health Policy Studies, Department of Medicine,
                           Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA (JPAI)
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><em>Correspondence to:</em> John P. A. Ioannidis, MD, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110,
                        Greece (e-mail: <span class="em-link"><span class="em-addr">jioannid{at}cc.uoi.gr</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2006-03-29"><span class="received-label">Received </span>March 29, 2006.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2006-07-10"><span class="rev-recd-label">Revision received </span>July 10, 2006.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2006-07-28"><span class="accepted-label">Accepted </span>July 28, 2006.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-1" title="MATERIALS AND METHODS" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  
                  <p id="p-1"><em>Background:</em> Aromatase inhibitors and inactivators have been extensively tested in patients with advanced breast cancer, but it is unclear
                     whether they offer any survival benefits compared with standard hormonal treatment with tamoxifen or progestagens. We performed
                     a meta-analysis of randomized controlled trials that compared several generations of aromatase inhibitors and inactivators
                     with standard hormonal treatment in patients with advanced breast cancer. <em>Methods:</em> The endpoint that we assessed was survival. Trials were located through searches of PubMed and Cochrane Library (last update
                     March 2006). Relative hazards (RHs) were summarized across trials through fixed- and random-effects analyses, and heterogeneity
                     was assessed with the <em>Q</em> and <em>I</em><sup>2</sup> statistics. All statistical tests were two-sided. <em>Results:</em> Twenty-five different comparisons, with a total of 8504 patients, were included in the meta-analysis. We found statistically
                     significant survival benefits with third-generation aromatase inhibitors and inactivators (vorozole, letrozole, examestane,
                     and anastrazole) (RH = 0.87, 95% confidence interval [CI] = 0.82 to 0.93; <em>P</em>&lt;.001) but not with first-generation (aminoglutethimide) or second-generation (formestane and fadrozole) agents. The difference
                     in the summary effects between these two groups of trials was statistically significant (<em>P</em> = .04). The survival benefit with third-generation agents in first-line trials, in which these agents were compared with
                     tamoxifen (11% RH reduction, 95% CI = 1% to 19%; <em>P</em> = .03), was identical to their benefit in second- and subsequent-line trials in which these agents were compared with other
                     treatments (14% RH reduction, 95% CI = 6% to 21%; <em>P</em>&lt;.001). <em>Conclusions:</em> Inhibition of the aromatase system, in particular with third-generation aromatase inhibitors and inactivators, appears to
                     be associated with statistically significant improved survival of patients with advanced breast cancer compared with standard
                     hormonal treatments.
                  </p>
                  
               </div>
               <p id="p-2">Breast cancer is the most common cancer in women <em>(<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>)</em>. Although most major advances have occurred in the treatment of early-stage disease, effective systemic therapies (chemotherapy
                  or hormone therapy) would have even more impact if they could also prolong the life of patients with advanced breast cancer
                  <em>(<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>).</em> Several regimens have been tested to identify treatments that may improve survival of patients with advanced breast cancer.
                  Tamoxifen and several progestagen compounds with antiestrogenic action (e.g., medroxyprogesterone acetate and megestrol acetate)
                  have been extensively used for first- and second-line treatments, respectively, of such patients. Aromatase inhibitors and
                  inactivators, which have documented benefits in early-stage disease <em>(<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>)</em>, are also being used to treat patients with advanced breast cancer, but their effectiveness in these patients has been more
                  controversial. Thirty randomized controlled trials have compared aromatase inhibitors with standard hormonal therapy in patients
                  with advanced breast cancer <em>(<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>–<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>)</em>, but it is unclear whether these agents offer a survival benefit. A recent meta-analysis suggested that, as second-line therapy,
                  these agents have similar outcomes to progestagen agents in terms of disease progression or overall response rates <em>(<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>).</em> However, giving priority to the use of these agents would be contentious unless a clear survival benefit can be documented.
                  Moreover, different aromatase inhibitors and inactivators may have different survival effects. Various agents of this class
                  have been developed over the last three decades that belong to different generations of drug development with different pharmacologic
                  profiles. These differences reflect various chemical structures and pharmacodynamics and may also be clinically relevant.
               </p>
               <p id="p-3">To address whether aromatase inhibitors and inactivators of different generations offer survival benefits, we performed a
                  meta-analysis of randomized trials among patients with advanced breast cancer, in which aromatase inhibitors or inactivators
                  were compared with the standard hormonal treatments in a first-line or second-line (or subsequent-line) setting. We identified
                  and systematically organized the cumulative evidence from randomized studies of the impact of systemic therapies on survival
                  of patients with advanced breast cancer. We also evaluated whether specific aromatase inhibitors had superior efficacy to
                  standard hormonal therapy and whether the benefits, if present, extended over the first-line treatment and subsequent lines
                  of treatment, regardless of the hormonal therapy used as comparator.
               </p>
               <div class="section" id="sec-1">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-6" title="RESULTS" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>M<span class="sc">ATERIALS AND</span> M<span class="sc">ETHODS</span></h2>
                  
                  
                  <h3>Identification of Randomized Studies</h3>
                  
                  <p id="p-4">We searched the Cochrane Central Trials Registry and PubMed without year and language restriction. The last search was updated
                     in March 2006. We used the searching algorithm (breast OR mammary) AND (cancer OR carcinoma OR neopl*) AND (aromatase OR aromatase
                     inhibitors OR AIs OR aminoglutethimide OR formestane OR fadrozole OR anastrazole OR letrozole OR exemestane OR vorozole) AND
                     (clinical trial OR randomized controlled trial OR double-blind OR single-blind OR single-blind OR random OR randomized OR
                     placebo).
                  </p>
                  
                  
                  
                  <h3>Eligibility Criteria</h3>
                  
                  <p id="p-5">We considered all randomized controlled trials to be eligible that compared an aromatase inhibitor or inactivator with tamoxifen
                     or progestagens (such as medroxyprogesterone acetate, megestrol acetate, or fluoxymesterone) in patients with advanced breast
                     cancer (i.e., metastatic and inoperable locally advanced or recurrent breast adenocarcinoma) in any line of treatment (first
                     [front] line or second or subsequent line [in patients who had received such hormonal therapy in the past]). Trials were eligible
                     regardless of the doses and schedules used for the regimens compared.
                  </p>
                  
                  <p id="p-6">We excluded trials in which the randomization was limited to earlier stages of the disease (patients with less than stage
                     IV disease) and trials that compared regimens in breast malignancies of histologic type other than adenocarcinoma (e.g., inflammatory
                     breast cancer or sarcoma). We also excluded meeting abstracts (because they had not undergone full peer review and should
                     be considered as preliminary reports open to modification), single-arm studies, dose-escalation studies, and nonrandomized
                     and pseudorandomized trials (e.g., those with alternate allocation of subjects).
                  </p>
                  
                  <p id="p-7">Trials that used other concomitant anticancer treatments (e.g., surgery, radiotherapy, or radioisotopic treatment) were eligible
                     if these treatments did not differ systematically between the investigated arms. Trials in which the compared arms differed
                     systematically in the use of these additional disease-related treatments were, however, excluded because the differences in
                     survival could not necessarily be attributed to the comparison of aromatase inhibitor treatment with standard hormonal treatment.
                  </p>
                  
                  <p id="p-8">Whenever multiple reports pertained to overlapping groups of patients, we retained only the report with longest follow-up
                     (largest number of events) for the meta-analysis calculations to avoid duplication of information. Data from interim analyses
                     were eligible if no further final data were available.
                  </p>
                  
                  
                  
                  <h3>Data Extraction and Outcomes</h3>
                  
                  <p id="p-9">From each eligible trial, we recorded the following items for both arms: authors' names; journal and year of publication;
                     country of origin; years of patient enrollment; number of centers involved; number of patients randomly assigned and analyzed
                     per arm, age, tumor stage, and menopausal status; hormonal receptor status; the exact regimens used and their dose and schedule;
                     the line of treatment; and any additional treatments given to both arms. We recorded study design items, including whether
                     there was a description of the mode of randomization, allocation concealment, the number of withdrawals per arm, and blinding
                     <em>(<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>)</em> and whether any planned or unplanned interim analyses had been performed <em>(<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>)</em>. We also recorded the median survival by arm and whether any statistically significant difference had been detected between
                     the compared arms at a <em>P</em> value of .05.
                  </p>
                  
                  
                  
                  <h3>Statistical Analysis</h3>
                  
                  <p id="p-10">We determined and combined relative hazards (RHs) of mortality for the comparison of aromatase inhibitors or inactivators
                     against standard hormonal treatment across the eligible studies. The natural logarithms of the relative hazards were combined
                     by use of general variance models that weighed each study by the inverse of its variance <em>(<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>)</em>. We assessed the statistical significance of between-study heterogeneity with the chi-square–based <em>Q</em> statistic (considered statistically significant for <em>P</em>&lt;.10) and used the <em>I</em><sup>2</sup> statistic to examine the extent of between-study heterogeneity (considered large for <em>I</em><sup>2</sup> values of 50%–74% and very large for <em>I</em><sup>2</sup> values of 75% and higher) <em>(<a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a>)</em>. Data were combined with both fixed- and random-effects models. In the absence of between-study heterogeneity, the two models
                     give identical results. With between-study heterogeneity, the random effects tend to give wider confidence intervals (CIs)
                     because they also incorporate a between-study variance in the within-study variance of each study.
                  </p>
                  
                  <p id="p-11">We used estimates of relative hazard derived from Cox proportional hazards models, whenever these values were reported in
                     analyses of the individual-level data done by the primary investigators. The standard deviation of logarithms of the relative
                     hazard was estimated as the difference of the upper minus the lower 95% confidence interval divided by 3.92. The variance
                     was then estimated as the square of the standard error. Whenever relative hazard estimates from Cox models were not provided,
                     we estimated the logarithms of the relative hazard and its variance from presented information with the <em>P</em> value from the log-rank test and events by patients, by arm, and/or by median survival by arm. When the number of events
                     per arm (<em>E</em><sub>1</sub> and <em>E</em><sub>2</sub>) was provided, we calculated the variance of the logarithm of the relative hazard by the sum of 1/<em>E</em><sub>1</sub> and 1/<em>E</em><sub>2</sub> <em>(<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>)</em>; we then calculated the logarithm of the relative hazard, so that its <em>P</em> value would be the same as the <em>P</em> value from the log-rank test. If the <em>P</em> value from a log-rank test was not available, we calculated the relative hazard as the inverse of the ratio of the two median
                     survival times by assuming exponential survival curves and proportional hazards.
                  </p>
                  
                  <p id="p-12">We considered trials in which two arms with different doses of aromatase inhibitor were compared with a third arm of an antiestrogen
                     agent as including two comparisons, unless the investigators only presented data merging the two aromatase inhibitor arms.
                     The same strategy was applied when investigators presented results from two similar trials in the same report.
                  </p>
                  
                  <p id="p-13">We analyzed data separately according to the generation of the agent (first-generation [aminoglutethimide] and second-generation
                     [formestane and fadrozole] inhibitors and inactivators versus third-generation inhibitors and inactivators [vorozole, letrozole,
                     examestane, and anastrazole]) because typically third-generation agents are currently used. We then performed subgroup analyses
                     according to type of comparison (tamoxifen versus other) and line of treatment (first versus second or subsequent line). These
                     two subgroup analyses are identical because tamoxifen was always the agent used for comparison in first-line treatment trials
                     and progestagens were always the agents used for comparisons in subsequent-line trials.
                  </p>
                  
                  <p id="p-14">We evaluated whether summary effect sizes changed over time in cumulative meta-analysis and recursive cumulative meta-analysis
                     <em>(<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>)</em> and whether there was any evidence that the results of studies with more precision differed from those of studies with less
                     precision <em>(<a id="xref-ref-38-1" class="xref-bibr" href="#ref-38">38</a>)</em>. Finally, we examined the quality characteristics of the combined trials and investigated whether any studies with statistically
                     significant results had been stopped early as part of planned or unplanned interim analyses <em>(<a id="xref-ref-33-2" class="xref-bibr" href="#ref-33">33</a>)</em> and whether there was any evidence for time-dependent survival differences in any trials. In sensitivity analyses, we excluded
                     such trials from the calculations. Analyses were performed with SPSS version 13.0 (SPSS Inc, Chicago, IL) and with Comprehensive
                     Meta-Analysis version 2 (Biostat, Englewood, NJ). All statistical tests were two-sided.
                  </p>
                  
                  
               </div>
               <div class="section" id="sec-6">
                  <div class="section-nav"><a href="#sec-1" title="MATERIALS AND METHODS" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-13" title="DISCUSSION" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>R<span class="sc">ESULTS</span></h2>
                  
                  
                  <h3>Eligible Trials</h3>
                  
                  <p id="p-15">We identified 30 different trials that were potentially eligible for our study (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1</a>). Of these 30 trials, seven with a total of 1005 patients did not address survival because they were typically phase I/II
                     or II trials that had not collected survival information. Thus, the meta-analysis included a total of 23 eligible trials and
                     8504 patients <em>(<a id="xref-ref-4-2" class="xref-bibr" href="#ref-4">4</a>–<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>)</em>, of whom 4559 had been randomly assigned to receive aromatase inhibitors or inactivators and 3945 had been assigned to receive
                     standard hormonal treatments. Of these 23 trials, two had been jointly analyzed, and we used data from the combined analysis
                     that were stratified by trial <em>(<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>)</em>. The designs of another three trials included three randomized arms, each with two doses of aromatase inhibitor, compared
                     with an antiestrogen agent, and these trials were analyzed as two comparisons per trial <em>(<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>–<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>).</em> A total of 25 comparisons were thus evaluated in this meta-analysis.
                     
                  </p>
                  <div id="F1" class="fig pos-float odd">
                     <div class="fig-inline"><a href="1285/F1.expansion.html"><img alt="Fig. 1." src="1285/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="1285/F1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1285/F1.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/98/18/1285/F1">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Fig. 1.</strong></span> 
                        <p id="p-16" class="first-child">Screened, excluded, and included articles and studies in the meta-analysis.</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  
                  
                  <h3>Trial Characteristics</h3>
                  
                  <p id="p-17"><a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a> shows the key characteristics of the 23 included trials (25 comparisons). In all, we included six comparisons of the first-generation
                     aromatase inhibitor aminoglutethimide, seven comparisons of second-generation inhibitors or inactivators (fadrozole or formestane),
                     and 12 comparisons of third-generation inhibitors (anastrozole, letrozole, or vorozole) or inactivators (exemestane). Nine
                     comparisons, all of which pertained to first-line treatment, used tamoxifen as the comparator, whereas the other 16 comparisons
                     involved second- or even third-line treatment with progestagens (i.e., megestrol acetate or medroxyprogesterone acetate).
                     One male patient was included in one early trial <em>(<a id="xref-ref-4-3" class="xref-bibr" href="#ref-4">4</a>)</em>, and a small number of perimenopausal women were included in some trials; otherwise, all trials included exclusively postmenopausal
                     women (<a id="xref-table-wrap-1-2" class="xref-table" href="#T1">Table 1</a>). The median age was between 57 and 68 years across treatment arms. Hormone receptor status had been ascertained to various
                     degrees across trials, but documented hormone receptor–negative cases were typically rare (<a id="xref-table-wrap-1-3" class="xref-table" href="#T1">Table 1</a>). Data on crossover to the alternative treatment arm were not always available, but crossover seemed to be substantial in
                     some trials (<a id="xref-table-wrap-1-4" class="xref-table" href="#T1">Table 1</a>).
                     
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1285/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1285/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 1.</strong> </span> 
                        <p id="p-18" class="first-child">Characteristics of eligible trials*</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  
                  
                  <h3>Design and Quality Characteristics</h3>
                  
                  <p id="p-22">Eleven trials were double blind <em>(<a id="xref-ref-9-2" class="xref-bibr" href="#ref-9">9</a>,<a id="xref-ref-10-3" class="xref-bibr" href="#ref-10">10</a>,<a id="xref-ref-17-3" class="xref-bibr" href="#ref-17">17</a>,<a id="xref-ref-18-2" class="xref-bibr" href="#ref-18">18</a>,<a id="xref-ref-21-3" class="xref-bibr" href="#ref-21">21</a>–<a id="xref-ref-24-4" class="xref-bibr" href="#ref-24">24</a>)</em>, 16 described in detail the mode of randomization <em>(<a id="xref-ref-6-2" class="xref-bibr" href="#ref-6">6</a>,<a id="xref-ref-9-3" class="xref-bibr" href="#ref-9">9</a>–<a id="xref-ref-11-2" class="xref-bibr" href="#ref-11">11</a>,<a id="xref-ref-14-2" class="xref-bibr" href="#ref-14">14</a>,<a id="xref-ref-17-4" class="xref-bibr" href="#ref-17">17</a>,<a id="xref-ref-18-3" class="xref-bibr" href="#ref-18">18</a>,<a id="xref-ref-20-2" class="xref-bibr" href="#ref-20">20</a>,<a id="xref-ref-21-4" class="xref-bibr" href="#ref-21">21</a>,<a id="xref-ref-23-3" class="xref-bibr" href="#ref-23">23</a>,<a id="xref-ref-24-5" class="xref-bibr" href="#ref-24">24</a>,<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>)</em>, 15 described some method for ensuring allocation concealment <em>(<a id="xref-ref-6-3" class="xref-bibr" href="#ref-6">6</a>,<a id="xref-ref-9-4" class="xref-bibr" href="#ref-9">9</a>,<a id="xref-ref-10-4" class="xref-bibr" href="#ref-10">10</a>,<a id="xref-ref-14-3" class="xref-bibr" href="#ref-14">14</a>,<a id="xref-ref-17-5" class="xref-bibr" href="#ref-17">17</a>,<a id="xref-ref-18-4" class="xref-bibr" href="#ref-18">18</a>,<a id="xref-ref-20-3" class="xref-bibr" href="#ref-20">20</a>,<a id="xref-ref-21-5" class="xref-bibr" href="#ref-21">21</a>,<a id="xref-ref-23-4" class="xref-bibr" href="#ref-23">23</a>,<a id="xref-ref-24-6" class="xref-bibr" href="#ref-24">24</a>,<a id="xref-ref-28-2" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-29-2" class="xref-bibr" href="#ref-29">29</a>)</em>, and 18 described withdrawals in sufficient detail <em>(<a id="xref-ref-5-2" class="xref-bibr" href="#ref-5">5</a>–<a id="xref-ref-9-5" class="xref-bibr" href="#ref-9">9</a>,<a id="xref-ref-13-2" class="xref-bibr" href="#ref-13">13</a>–<a id="xref-ref-20-4" class="xref-bibr" href="#ref-20">20</a>,<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>–<a id="xref-ref-29-3" class="xref-bibr" href="#ref-29">29</a>)</em>. No trials were stopped early because of statistically significant survival differences in an interim analysis.
                  </p>
                  
                  
                  
                  <h3>Meta-analysis</h3>
                  
                  <p id="p-23">Meta-analysis according to generation of aromatase inhibitor (<a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a> and <a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 2</a>) found that only third-generation aromatase inhibitors and inactivators (RH = 0.87, 95% CI = 0.82 to 0.93; <em>P</em>&lt;.001) were statistically significantly associated with increased survival compared with standard hormone therapy. There was
                     no evidence of any increased survival with aminoglutethimide and second-generation agents (RH = 0.98, 95% CI = 0.90 to 1.07).
                     The difference in the summary effects between these two groups of trials was statistically significant (<em>P</em> = .04). A combination of the data across all 25 available comparisons also provided a statistically significant summary effect
                     for mortality (RH = 0.91, 95% CI = 0.86 to 0.96; <em>P</em> = .001). There was no statistically significant between-study heterogeneity when all studies were considered (<em>Q</em> = 22.8 with 24 df), possibly because of the relatively wide confidence intervals of single trials.
                     
                     
                  </p>
                  <div id="F2" class="fig pos-float odd">
                     <div class="fig-inline"><a href="1285/F2.expansion.html"><img alt="Fig. 2." src="1285/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="1285/F2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1285/F2.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/98/18/1285/F2">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Fig. 2.</strong></span> 
                        <p id="p-24" class="first-child">Meta-analysis of survival for the comparison between aromatase inhibitors or inactivators and standard hormonal therapy. <strong>Upper</strong>) First- and second-generation agents. <strong>Lower</strong>) Third-generation agents. Each trial is identified by the name of the tested aromatase inhibitor or inactivator and the name
                           of the first author or trial/protocol name/abbreviation. The point estimate for the relative hazard and its 95% confidence
                           interval (CI) are indicated as a circle and whiskers, respectively. Also shown is the summary estimate and its 95% CI (results
                           from fixed- and random-effects analyses were identical or very similar, as noted in <a id="xref-table-wrap-2-2" class="xref-table" href="#T2">Table 2</a>).
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div class="table pos-float" id="T2">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1285/T2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1285/T2.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 2.</strong> </span> 
                        <p id="p-25" class="first-child">Summary estimates and subgroup analyses*</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  
                  
                  <h3>Treatment Line</h3>
                  
                  <p id="p-27">The survival benefit for third-generation agents was practically identical in both first-line trials, in which the comparator
                     was tamoxifen (11% RH reduction, 95% CI = 1% to 19%; <em>P</em> = .03), and second-line (or subsequent-line) trials, in which progestagen comparators were used (14% RH reduction, 95% CI
                     = 6% to 21%; <em>P</em>&lt;.001). There was no between-study heterogeneity in either of these two subgroups. There was no statistically significant
                     benefit observed with first- or second-generation agents (RH = 0.97 and 0.99, respectively, for first-line and second-line
                     [or subsequent-line] trials) (<a id="xref-table-wrap-2-3" class="xref-table" href="#T2">Table 2</a>).
                  </p>
                  
                  
                  
                  <h3>Bias Diagnostics</h3>
                  
                  <p id="p-28">In cumulative meta-analysis of all trials, no statistically significant effect on survival was found in the trials published
                     through 1997. A nominally statistically significant effect was detected in trials published through the end of 1998 (summary
                     RH = 0.93, 95% CI = 0.86 to 1.00; <em>P</em> = .047); this effect was temporarily lost by the end of 1999 (summary RH = 0.94, 95% CI = 0.88 to 1.00; <em>P</em> = .054) and reappeared in 2000 with the publication of an exemestane trial <em>(<a id="xref-ref-24-7" class="xref-bibr" href="#ref-24">24</a>)</em>. The relative hazard has continued to remain in the range of 0.91–0.92 and to be statistically significant through 2006.
                     This pattern is consistent with the later introduction of third-generation agents in clinical trials. There was no major change
                     in the magnitude of the effect when cumulative meta-analyses were performed separately by generation of aromatase inhibitor.
                  </p>
                  
                  <p id="p-29">There was no evidence that less precise or smaller trials gave different results from more precise or larger trials. This
                     lack of significant difference between less and more precise trials was true across all trials (tau = 0.18 and <em>P</em> = .21) and when limited to trials of third-generation aromatase inhibitors and exemestane (tau = −0.26 and <em>P</em> = .24).
                  </p>
                  
                  <p id="p-30">Four of the 25 comparisons showed statistically significant results on their own (three with third-generation aromatase inhibitors
                     and one with exemestane). None of the trials with statistically significant differences had been stopped early in an interim
                     analysis. Finally, one trial <em>(<a id="xref-ref-9-6" class="xref-bibr" href="#ref-9">9</a>)</em> suggested that the difference between the two compared arms varied according to the duration of follow-up: a survival benefit
                     was seen between 6 and 20 months of follow-up but not over the total trial duration. No formal test of time dependence was
                     performed in that trial. When we excluded this trial from our analysis, the summary relative hazard was unchanged.
                  </p>
                  
                  
               </div>
               <div class="section" id="sec-13">
                  <div class="section-nav"><a href="#sec-6" title="RESULTS" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>D<span class="sc">ISCUSSION</span></h2>
                  
                  <p id="p-31">This meta-analysis showed that treatment with aromatase inhibitors and inactivators, in particular the newer third-generation
                     agents, is associated with increased survival among patients with advanced breast cancer. This association was apparent in
                     the first-, second-, and subsequent-line treatment settings. Tamoxifen and progestagens have been the agents used in standard
                     hormonal treatment of advanced breast cancer in the first- and second-line settings, respectively <em>(<a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39</a>)</em>, even though aromatase inhibitors and inactivators are already widely used in the Western world. Our findings may challenge
                     this standard of care, not only for second-line treatment—in which aromatase inhibitors are increasingly accepted on an equal
                     or better standing than progestagens <em>(<a id="xref-ref-31-2" class="xref-bibr" href="#ref-31">31</a>)</em>—but also for first-line treatment, in which tamoxifen has largely remained the first choice to date. It is common practice
                     for patients with hormone receptor–positive advanced breast cancer to receive both tamoxifen and an aromatase inhibitor, typically
                     in sequence. Our results indicate that aromatase inhibitors and inactivators should be the first-line therapy for such patients.
                     The association between increased survival and treatment with aromatase inhibitors and inactivators did not seem to extend
                     to first- and second-generation agents. These earlier agents also tend to have less favorable tolerability profiles.
                  </p>
                  
                  <p id="p-32">The estimated benefits reflect the intention-to-treat analyses, but we should caution that crossover in some trials <em>(<a id="xref-ref-6-4" class="xref-bibr" href="#ref-6">6</a>,<a id="xref-ref-9-7" class="xref-bibr" href="#ref-9">9</a>)</em> may have even diluted the treatment differences. The particular benefits of third-generation agents may be due to many reasons.
                     Third-generation aromatase inhibitors and inactivators are more selective than first- and second-generation agents and are
                     apparently less toxic <em>(<a id="xref-ref-9-8" class="xref-bibr" href="#ref-9">9</a>,<a id="xref-ref-40-1" class="xref-bibr" href="#ref-40">40</a>)</em>, and they also have a convenient pharmacologic profile that allows easier dosing <em>(<a id="xref-ref-41-1" class="xref-bibr" href="#ref-41">41</a>).</em> Given the demonstrated survival benefit of third-generation agents compared with standard hormonal therapy, our results may
                     represent a departure from the standard management of advanced breast cancer with hormonal therapy that has been used for
                     the last two decades. The standard of care may need to be reconsidered. Both efficacy and tolerability also need to be taken
                     into account in clinical decision making. The available evidence suggests that aromatase inhibitors cause less weight gain,
                     dyspnea, and peripheral edema than progestins but that they may cause more hot flushes <em>(<a id="xref-ref-31-3" class="xref-bibr" href="#ref-31">31</a>)</em>. The balance of toxicities is also not unfavorable when compared with the toxicities associated with tamoxifen, and, in some
                     trials, tolerability is actually substantially better for aromatase inhibitors than for tamoxifen <em>(<a id="xref-ref-9-9" class="xref-bibr" href="#ref-9">9</a>,<a id="xref-ref-10-5" class="xref-bibr" href="#ref-10">10</a>)</em>. For some serious adverse events, such as thrombosis, more studies are required to determine the relative risk associated
                     with aromatase inhibitors compared with tamoxifen, but the current evidence does not suggest that aromatase inhibitors are
                     worse <em>(<a id="xref-ref-42-1" class="xref-bibr" href="#ref-42">42</a>)</em>. Increased quality of life has also been demonstrated with aromatase inhibitors compared with tamoxifen <em>(<a id="xref-ref-43-1" class="xref-bibr" href="#ref-43">43</a>)</em>.
                  </p>
                  
                  <p id="p-33">The absolute magnitude of the survival benefit also needs to be considered. For a theoretical group of patients with an expected
                     median survival of 30 months with standard hormonal treatment, we estimate from our data that the increased median survival
                     conferred by a third-generation aromatase inhibitor or inactivator is about 4 months (13% RH reduction and assuming exponential
                     mortality curves). These 4 months can be a considerable survival benefit for an advanced-stage patient <em>(<a id="xref-ref-44-1" class="xref-bibr" href="#ref-44">44</a>).</em> However, for women with median survival of 10 months, the expected benefit would slightly exceed only 1 month. These calculations
                     make the assumption of a similar relative hazard reduction for patients at different levels of risk, and they would not be
                     true if this hypothesis is violated.
                  </p>
                  
                  <p id="p-34">Some limitations of our study need to be discussed. First, it may be useful to perform a meta-analysis of individual-level
                     data that targets outcomes separately by subgroups of patients who have various risks of death <em>(<a id="xref-ref-45-1" class="xref-bibr" href="#ref-45">45</a>).</em> Second, our meta-analysis is based on data from trials whose results have published, and we note that publication bias is
                     a potential threat to the validity of the results. Third, we did not obtain updated individual patient data, the use of such
                     data might have further enhanced the accuracy and reduced the uncertainty of the estimates <em>(<a id="xref-ref-46-1" class="xref-bibr" href="#ref-46">46</a>,<a id="xref-ref-47-1" class="xref-bibr" href="#ref-47">47</a>).</em> However, we found no evidence of between-study heterogeneity and no hint of bias across several pertinent diagnostics. Allowing
                     for these caveats, the meta-analysis offers strong evidence for the use of third-generation aromatase inhibitors and inactivators
                     in the treatment of advanced breast cancer.
                  </p>
                  
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-13" title="DISCUSSION" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-5">
                        
                        <p id="p-35">The authors have full responsibility for the design of the study, the collection of the data, the analysis and interpretation
                           of the data, the decision to submit the manuscript for publication, and the writing of the manuscript.
                        </p>
                        
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© The Author 2006. Published by Oxford University Press.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">(1)</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference (1) in text"
                           id="ref-1">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.1"
                             data-doi="10.3322/canjclin.50.1.7">
                           <div class="cit-metadata"><cite>Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. <span class="cit-source">CA Cancer J Clin</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">50</span>:<span class="cit-fpage">7</span>–33.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.3322/canjclin.50.1.7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10735013&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000084859700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(2)</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference (2) in text"
                           id="ref-2">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.2"
                             data-doi="10.1053/ctrv.1999.0161">
                           <div class="cit-metadata"><cite>Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast
                                 cancer. <span class="cit-source">Cancer Treat Rev</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">26</span>:<span class="cit-fpage">151</span>–68.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1053/ctrv.1999.0161&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10814559&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000087350900001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(3)</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference (3) in text"
                           id="ref-3">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.3"
                             data-doi="10.1016/S0140-6736(02)09088-8">
                           <div class="cit-metadata"><cite>Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus
                                 tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised
                                 trial. <span class="cit-source">Lancet</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">359</span>:<span class="cit-fpage">2131</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(02)09088-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12090977&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176441800006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(4)</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference (4) in text"
                           id="ref-4">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.4">
                           <div class="cit-metadata"><cite>Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide
                                 in the treatment of advanced breast carcinoma. <span class="cit-source">Cancer Res</span> <span class="cit-pub-date">1982</span>;<span class="cit-vol">42</span>:<span class="cit-fpage">3430</span>–3.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=A1982PG90700036&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(5)</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference (5) in text"
                           id="ref-5">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.5"
                             data-doi="10.1002/1097-0142(19940115)73:2&lt;354::AID-CNCR2820730220&gt;3.0.CO;2-J">
                           <div class="cit-metadata"><cite>Gale KE, Andersen JW, Tormey DC, Mansour EG, Davis TE, Horton J, et al. Hormonal treatment for metastatic breast cancer. An
                                 Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. <span class="cit-source">Cancer</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">73</span>:<span class="cit-fpage">354</span>–61.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19940115)73:2%3C354::AID-CNCR2820730220%3E3.0.CO;2-J&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8293400&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1994MR38100019&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(6)</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference (6) in text"
                           id="ref-6">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.6">
                           <div class="cit-metadata"><cite>Thurlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, et al. First-line fadrozole HCI (CGS 16949A)
                                 versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for
                                 Clinical Cancer Research SAKK 20/88. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">7</span>:<span class="cit-fpage">471</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=7/5/471"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(7)</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference (7) in text"
                           id="ref-7">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.7">
                           <div class="cit-metadata"><cite>Falkson CI, Falkson HC. A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal
                                 patients with metastatic breast cancer. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">7</span>:<span class="cit-fpage">465</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=7/5/465"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(8)</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference (8) in text"
                           id="ref-8">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.8">
                           <div class="cit-metadata"><cite>Perez-Carrion R, Alberola Candel V, Calabresi F, Michel RT, Santos R, Delozier T, et al. Comparison of the selective aromatase
                                 inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">5</span>:<span class="cit-fpage">S19</span>–24.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(9)</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference (9) in text"
                           id="ref-9">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.9">
                           <div class="cit-metadata"><cite>Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen
                                 as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International
                                 Letrozole Breast Cancer Group. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>:<span class="cit-fpage">2596</span>–606.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/10/2596"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(10)</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference (10) in text"
                           id="ref-10">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.10"
                             data-doi="10.1016/S0959-8049(03)00326-5">
                           <div class="cit-metadata"><cite>Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy
                                 for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">39</span>:<span class="cit-fpage">1684</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0959-8049(03)00326-5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12888362&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000184669700006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(11)</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference (11) in text"
                           id="ref-11">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.11"
                             data-doi="10.1097/00000421-200306000-00022">
                           <div class="cit-metadata"><cite>Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, et al. Anastrozole versus tamoxifen as first-line therapy in
                                 postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. <span class="cit-source">Am J Clin Oncol</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">26</span>:<span class="cit-fpage">317</span>–22.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/00000421-200306000-00022&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12796608&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000183506300022&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(12)</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference (12) in text"
                           id="ref-12">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.12">
                           <div class="cit-metadata"><cite>Castelazo Rico G, Molotla Xolalpa D, Basavilvazo Rodriguez MA, Angeles Victoria L, Zarate A, Hernandez Valencia M. Survival
                                 of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen. <span class="cit-source">Ginecol Obstet Mex</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">72</span>:<span class="cit-fpage">493</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=15790189&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(13)</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference (13) in text"
                           id="ref-13">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.13">
                           <div class="cit-metadata"><cite>Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, et al. Second and third line hormonotherapy in advanced
                                 post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide
                                 in patients who have become resistant to tamoxifen. <span class="cit-source">Breast Cancer Res Treat</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">24</span>:<span class="cit-fpage">139</span>–45.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(14)</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference (14) in text"
                           id="ref-14">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.14"
                             data-doi="10.1093/jnci/80.14.1147">
                           <div class="cit-metadata"><cite>Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D. Randomized trial comparing aminoglutethimide with high-dose
                                 medroxyprogesterone acetate in therapy for advanced breast carcinoma. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">1988</span>;<span class="cit-vol">80</span>:<span class="cit-fpage">1147</span>–51.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=80/14/1147"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(15)</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference (15) in text"
                           id="ref-15">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.15"
                             data-doi="10.1007/BF01810736">
                           <div class="cit-metadata"><cite>Lundgren S, Gundersen S, Klepp R, Lonning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic
                                 breast cancer. <span class="cit-source">Breast Cancer Res Treat</span> <span class="cit-pub-date">1989</span>;<span class="cit-vol">14</span>:<span class="cit-fpage">201</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/BF01810736&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2690972&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989CA42900002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(16)</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference (16) in text"
                           id="ref-16">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.16">
                           <div class="cit-metadata"><cite>Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, et al. Megestrol acetate and aminoglutethimide/hydrocortisone
                                 in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest
                                 Oncology Group phase III trial. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">2494</span>–501.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=15/7/2494"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(17)</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference (17) in text"
                           id="ref-17">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.17"
                             data-doi="10.1002/(SICI)1097-0142(19960615)77:12&lt;2503::AID-CNCR13&gt;3.0.CO;2-W">
                           <div class="cit-metadata"><cite>Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment
                                 of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional
                                 trials. <span class="cit-source">Cancer</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">77</span>:<span class="cit-fpage">2503</span>–13.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0142(19960615)77:12%3C2503::AID-CNCR13%3E3.0.CO;2-W&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8640699&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996UN53800013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(18)</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference (18) in text"
                           id="ref-18">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.18"
                             data-doi="10.1159/000011888">
                           <div class="cit-metadata"><cite>Bezwoda WR, Gudgeon A, Falkson G, Jordaan JP, Goedhals L. Fadrozole versus megestrol acetate: a double-blind randomised trial
                                 in advanced breast cancer. <span class="cit-source">Oncology</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">55</span>:<span class="cit-fpage">416</span>–20.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1159/000011888&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9732218&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000075703200007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(19)</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference (19) in text"
                           id="ref-19">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.19">
                           <div class="cit-metadata"><cite>Goss PE, Winer EP, Tannock IF, Schwartz LH. Randomized phase III trial comparing the new potent and selective third-generation
                                 aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole
                                 Study Group. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>:<span class="cit-fpage">52</span>–63.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=17/1/52"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(20)</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference (20) in text"
                           id="ref-20">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.20"
                             data-doi="10.1054/brst.1999.0118">
                           <div class="cit-metadata"><cite>Freue M, Kjaer M, Boni C, Joliver J, Janicke F, Willemse PH, et al. Open comparative trial of formestane versus megestrol
                                 acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. <span class="cit-source">Breast</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">9</span>–16.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1054/brst.1999.0118&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=14731578&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000086098600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(21)</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference (21) in text"
                           id="ref-21">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.21">
                           <div class="cit-metadata"><cite>Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for
                                 advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared
                                 with megestrol acetate. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">16</span>:<span class="cit-fpage">453</span>–61.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=16/2/453"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(22)</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference (22) in text"
                           id="ref-22">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.22">
                           <div class="cit-metadata"><cite>Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, et al. Phase III, multicenter, double-blind, randomized study
                                 of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>:<span class="cit-fpage">3357</span>–66.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/14/3357"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(23)</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference (23) in text"
                           id="ref-23">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.23"
                             data-doi="10.1002/(SICI)1097-0142(19980915)83:6&lt;1142::AID-CNCR13&gt;3.0.CO;2-5">
                           <div class="cit-metadata"><cite>Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, et al. Anastrozole versus megestrol acetate in the treatment
                                 of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data
                                 from two mature phase III trials. Arimidex Study Group. <span class="cit-source">Cancer</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">83</span>:<span class="cit-fpage">1142</span>–52.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0142(19980915)83:6%3C1142::AID-CNCR13%3E3.0.CO;2-5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9740079&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000075830100013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(24)</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference (24) in text"
                           id="ref-24">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.24">
                           <div class="cit-metadata"><cite>Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen
                                 failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane
                                 Study Group. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">18</span>:<span class="cit-fpage">1399</span>–411.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=18/7/1399"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(25)</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference (25) in text"
                           id="ref-25">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.25">
                           <div class="cit-metadata"><cite>Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, et al. Randomized trial of aminoglutethimide versus tamoxifen
                                 in metastatic breast cancer. <span class="cit-source">Cancer Res</span> <span class="cit-pub-date">1982</span>;<span class="cit-vol">42</span>:<span class="cit-fpage">S3434</span>–6.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(26)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.18.1285.26">
                           <div class="cit-metadata"><cite>Samonis G, Margioris AN, Bafaloukos D, Razis DV. Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone
                                 acetate (MPA) versus AG+MPA in generalized breast cancer. <span class="cit-source">Oncology</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">51</span>:<span class="cit-fpage">411</span>–5.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8052481&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1994PD89200004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(27)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.18.1285.27">
                           <div class="cit-metadata"><cite>Alonso-Munoz MC, Ojeda-Gonzalez MB, Beltran-Fabregat M, Dorca-Ribugent J, Lopez-Lopez L, Borras-Balada J, et al. Randomized
                                 trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal
                                 breast cancer. <span class="cit-source">Oncology</span> <span class="cit-pub-date">1988</span>;<span class="cit-vol">45</span>:<span class="cit-fpage">350</span>–3.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3045726&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1988P951500004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(28)</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference (28) in text"
                           id="ref-28">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.28"
                             data-doi="10.1093/annonc/mdg362">
                           <div class="cit-metadata"><cite>Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, et al. Mature results of a randomized phase II multicenter study
                                 of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">14</span>:<span class="cit-fpage">1391</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=14/9/1391"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(29)</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference (29) in text"
                           id="ref-29">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.29"
                             data-doi="10.1016/S0959-8049(97)00105-6">
                           <div class="cit-metadata"><cite>Thurlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, et al. Formestane versus megestrol acetate in
                                 postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line
                                 hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">33</span>:<span class="cit-fpage">1017</span>–24.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0959-8049(97)00105-6&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9376181&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(30)</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference (30) in text"
                           id="ref-30">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.30">
                           <div class="cit-metadata"><cite>Hultborn R, Johansson-Terje I, Bergh J, Glas U, Hallsten L, Hatschek T, et al. Second-line endocrine treatment of advanced
                                 breast cancer—a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide. <span class="cit-source">Acta Oncol</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">35</span>:<span class="cit-fpage">s75</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(31)</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference (31) in text"
                           id="ref-31">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.31"
                             data-doi="10.1002/cncr.21339">
                           <div class="cit-metadata"><cite>Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papaldo P, et al. New aromatase inhibitors as second-line endocrine
                                 therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. <span class="cit-source">Cancer</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">104</span>:<span class="cit-fpage">1335</span>–42.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/cncr.21339&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16088965&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000232001200001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(32)</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference (32) in text"
                           id="ref-32">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.32">
                           <div class="cit-metadata unstructured">Cochrane Handbook.The Cochrane Handbook for Systematic Reviews of Interventions. Available at <a href="http://www.cochrane.org/resources/handbook/handbook.pdf">http://www.cochrane.org/resources/handbook/handbook.pdf</a>. [Last assessed: March 20, 2006.]
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(33)</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference (33) in text"
                           id="ref-33">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.33"
                             data-doi="10.1001/jama.294.17.2203">
                           <div class="cit-metadata"><cite>Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a
                                 systematic review. <span class="cit-source">JAMA</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">294</span>:<span class="cit-fpage">2203</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.294.17.2203&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16264162&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000232957700023&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(34)</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference (34) in text"
                           id="ref-34">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.34"
                             data-doi="10.7326/0003-4819-127-9-199711010-00008">
                           <div class="cit-metadata"><cite>Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. <span class="cit-source">Ann Intern Med</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">127</span>:<span class="cit-fpage">820</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.7326/0003-4819-127-9-199711010-00008&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9382404&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997YD89800007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(35)</span><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference (35) in text"
                           id="ref-35">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.35"
                             data-doi="10.1002/sim.1186">
                           <div class="cit-metadata"><cite>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">1539</span>–58.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1186&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111919&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(36)</span><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference (36) in text"
                           id="ref-36">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.36">
                           <div class="cit-metadata"><cite>Ioannidis JP, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, et al. Early or deferred zidovudine therapy in HIV-infected
                                 patients without an AIDS-defining illness. <span class="cit-source">Ann Intern Med</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">122</span>:<span class="cit-fpage">856</span>–66.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7741372&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995RA13900009&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(37)</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference (37) in text"
                           id="ref-37">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.37"
                             data-doi="10.1073/pnas.021529998">
                           <div class="cit-metadata"><cite>Ioannidis JP, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. <span class="cit-source">Proc Natl Acad Sci U S A</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">98</span>:<span class="cit-fpage">831</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=pnas&amp;resid=98/3/831"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(38)</span><a class="rev-xref-ref" href="#xref-ref-38-1" title="View reference (38) in text"
                           id="ref-38">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.38" data-doi="10.2307/2533446">
                           <div class="cit-metadata"><cite>Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. <span class="cit-source">Biometrics</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">50</span>:<span class="cit-fpage">1088</span>–101.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2307/2533446&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7786990&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1994QP05000016&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(39)</span><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference (39) in text"
                           id="ref-39">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.39"
                             data-doi="10.1093/annonc/mdi816">
                           <div class="cit-metadata"><cite>Kataja VV, Colleoni M, Bergh J; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment
                                 and follow-up of locally recurrent or metastatic breast cancer (MBC). <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">16</span>(Suppl 1):<span class="cit-fpage">i10</span>–2.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=PDF&amp;journalCode=annonc&amp;resid=16/suppl_1/i10"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(40)</span><a class="rev-xref-ref" href="#xref-ref-40-1" title="View reference (40) in text"
                           id="ref-40">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.40">
                           <div class="cit-metadata"><cite>Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line
                                 therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex
                                 Study Group. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">18</span>:<span class="cit-fpage">3758</span>–67.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=18/22/3758"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(41)</span><a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference (41) in text"
                           id="ref-41">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.41"
                             data-doi="10.1002/cncr.10908">
                           <div class="cit-metadata"><cite>Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation
                                 aromatase inhibitors anastrozole, letrozole, and exemestane. <span class="cit-source">Cancer</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">95</span>:<span class="cit-fpage">2006</span>–16.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/cncr.10908&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12404296&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000178807600024&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(42)</span><a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference (42) in text"
                           id="ref-42">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.42"
                             data-doi="10.1002/cncr.20347">
                           <div class="cit-metadata"><cite>Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma:
                                 a systematic review. <span class="cit-source">Cancer</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">101</span>:<span class="cit-fpage">439</span>–49.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/cncr.20347&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15274057&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000222770100002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(43)</span><a class="rev-xref-ref" href="#xref-ref-43-1" title="View reference (43) in text"
                           id="ref-43">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.43"
                             data-doi="10.1093/annonc/mdi275">
                           <div class="cit-metadata"><cite>Irish W, Sherrill B, Cole B, Gard C, Glendenning GA, Mouridsen H. Quality-adjusted survival in a crossover trial of letrozole
                                 versus tamoxifen in postmenopausal women with advanced breast cancer. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">16</span>:<span class="cit-fpage">1458</span>–62.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=16/9/1458"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(44)</span><a class="rev-xref-ref" href="#xref-ref-44-1" title="View reference (44) in text"
                           id="ref-44">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.44"
                             data-doi="10.1016/S0959-8049(03)00119-9">
                           <div class="cit-metadata"><cite>Ioannidis JP, Pavlidis N. Levels of absolute survival benefit for systemic therapies of advanced cancer: a call for standards.
                                 <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">39</span>:<span class="cit-fpage">1194</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0959-8049(03)00119-9&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12763206&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000183427600013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(45)</span><a class="rev-xref-ref" href="#xref-ref-45-1" title="View reference (45) in text"
                           id="ref-45">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.45"
                             data-doi="10.1016/S0895-4356(00)00311-5">
                           <div class="cit-metadata"><cite>Trikalinos TA, Ioannidis JP. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient
                                 data. <span class="cit-source">J Clin Epidemiol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">54</span>:<span class="cit-fpage">245</span>–52.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0895-4356(00)00311-5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11223322&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000167162300005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(46)</span><a class="rev-xref-ref" href="#xref-ref-46-1" title="View reference (46) in text"
                           id="ref-46">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.46"
                             data-doi="10.1177/0163278702025001006">
                           <div class="cit-metadata"><cite>Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient
                                 data. <span class="cit-source">Eval Health Prof</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">25</span>:<span class="cit-fpage">76</span>–97.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=spehp&amp;resid=25/1/76"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(47)</span><a class="rev-xref-ref" href="#xref-ref-47-1" title="View reference (47) in text"
                           id="ref-47">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.18.1285.47">
                           <div class="cit-metadata"><cite>Clarke M, Stewart L, Pignon JP, Bijnens L. Individual patient data meta-analysis in cancer. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">77</span>:<span class="cit-fpage">2036</span>–44.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9667689&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000080207600052&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">MEMO TO THE MEDIA<span class="cit-sep cit-sep-after-article-section">:</span> </span><ul class="cit-auth-list">
                           <li class="first-item"><span class="cit-auth cit-auth-type-author">Ariel Whitworth</span></li>  
                        </ul><span class="cit-title">Press Release<span class="cit-sep cit-sep-after-article-title">: </span><span class="cit-subtitle">Aromatase Inhibitors: A Treatment of Choice for Advanced Breast Cancer Patients </span> </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>20 September 2006<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">98 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>18<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1259</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djj418 </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>September 19, 2006 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;98/18/1259-a extract,full"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/98/18/1259.2.extract" rel="extract">Extract</a></li>
                           <li class="last-item"><a href="/content/98/18/1259.2.full" rel="full-text">Full Text (HTML)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/98/18/1275.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/98/18/1292.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/98/18.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (20 September 2006) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    98
                                    </span><span class="slug-issue">
                                    (18):
                                    </span><span class="slug-pages">
                                    1285-1291.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djj357" class="slug-doi">10.1093/jnci/djj357</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/98/18/1285.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/98/18/1285.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=ARTICLES&amp;sortspec=date&amp;submit=Submit">Article</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;98/18/1285" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B98%2F18%2F1285&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/98/18/1285.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=98/18/1285&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/98/18/1285.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3B98%2F18%2F1285&amp;citation=Mauri%20et%20al.%2098%20%2818%29:%201285&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B98%2F18%2F1285&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=16985247&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B98%2F18%2F1285">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B98%2F18%2F1285">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Survival%20With%20Aromatase%20Inhibitors%20and%20Inactivators%20Versus%20Standard%20Hormonal%20Therapy%20in%20Advanced%20Breast%20Cancer%3A%20Meta-analysis%3A%20&amp;publicationDate=20%20September%202006&amp;author=Davide%20Mauri%2C%20Nicholas%20Pavlidis%2C%20Nikolaos%20P.%20Polyzos%2C%20John%20P.%20A.%20Ioannidis&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjj357&amp;volumeNum=98&amp;issueNum=18&amp;startPage=1285&amp;endPage=1291&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/98/18/1285.full?cited-by=yes&amp;legid=jnci;98/18/1285#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/98/18/1285" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/98/18/1285?access_num=/jnci/98/18/1285"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F98%2F18%2F1285&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/98/18/1285.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AMauri%20author%3AD.%22"
                              class="cb-art-gs-auth author-link">Articles by  Mauri, D.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AIoannidis%20author%3AJ.P.A.%22"
                              class="cb-art-gs-auth author-link">Articles by  Ioannidis, J. P. A.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/98/18/1285.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=16985247&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Mauri%20D&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Mauri, D.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Pavlidis%20N&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Pavlidis, N.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Polyzos%20NP&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Polyzos, N. P.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Ioannidis%20JP&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Ioannidis, J. P. A.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/98/18/1285.full?related-urls=yes&amp;legid=jnci;98/18/1285#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B98%2F18%2F1285&amp;current-view-path=/content/98/18/1285.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/18/1285&amp;title=Survival%20With%20Aromatase%20Inhibitors%20and%20Inactivators%20Versus%20Standard%20Hormonal%20Therapy%20in%20Advanced%20Breast%20Cancer%3A%20Meta-analysis+--+Mauri%20et%20al.%2098%20%2818%29%3A%201285+--+&amp;doi=10.1093/jnci/djj357&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/18/1285&amp;title=Survival%20With%20Aromatase%20Inhibitors%20and%20Inactivators%20Versus%20Standard%20Hormonal%20Therapy%20in%20Advanced%20Breast%20Cancer%3A%20Meta-analysis+--+Mauri%20et%20al.%2098%20%2818%29%3A%201285+--+&amp;doi=10.1093/jnci/djj357&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/98/18/1285&amp;title=Survival%20With%20Aromatase%20Inhibitors%20and%20Inactivators%20Versus%20Standard%20Hormonal%20Therapy%20in%20Advanced%20Breast%20Cancer%3A%20Meta-analysis+--+Mauri%20et%20al.%2098%20%2818%29%3A%201285+--+&amp;doi=10.1093/jnci/djj357&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/18/1285&amp;title=Survival%20With%20Aromatase%20Inhibitors%20and%20Inactivators%20Versus%20Standard%20Hormonal%20Therapy%20in%20Advanced%20Breast%20Cancer%3A%20Meta-analysis+--+Mauri%20et%20al.%2098%20%2818%29%3A%201285+--+&amp;doi=10.1093/jnci/djj357&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/18/1285&amp;title=Survival%20With%20Aromatase%20Inhibitors%20and%20Inactivators%20Versus%20Standard%20Hormonal%20Therapy%20in%20Advanced%20Breast%20Cancer%3A%20Meta-analysis+--+Mauri%20et%20al.%2098%20%2818%29%3A%201285+--+&amp;doi=10.1093/jnci/djj357&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/18/1285&amp;title=Survival%20With%20Aromatase%20Inhibitors%20and%20Inactivators%20Versus%20Standard%20Hormonal%20Therapy%20in%20Advanced%20Breast%20Cancer%3A%20Meta-analysis+--+Mauri%20et%20al.%2098%20%2818%29%3A%201285+--+&amp;doi=10.1093/jnci/djj357&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-1">M<span class="sc">ATERIALS AND</span> M<span class="sc">ETHODS</span></a></li>
                        <li><a href="#sec-6">R<span class="sc">ESULTS</span></a></li>
                        <li><a href="#sec-13">D<span class="sc">ISCUSSION</span></a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/98/18/1285.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/98/18/1285.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>